Search
Pralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigational[A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment … It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986]
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsBelimumab
go.drugbank.com/drugs/DB08879ApprovedInvestigationalBelimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. … [A251495, L42705] By binding to BLyS and blocking its interaction with B cell receptors, belimumab inhibits the survival of B cells.
Categories: Decreased B Lymphocyte Activation, B Lymphocyte Stimulator-specific InhibitorProducts: BENLYSTA 200 MG / 1 ML, BENLYSTA SUBCUTÁNEO 200 MG / 1 MLProcaine
go.drugbank.com/drugs/DB00721ApprovedInvestigationalVet approvedProcaine has also been investigated as an oral entry inhibitor in treatment-experienced HIV patients [L1215]. … A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block.
Categories: NMDA Receptor AntagonistsSynonyms: 2-Diethylaminoethyl p-aminobenzoate, β-(diethylamino)ethyl 4-aminobenzoateNuclear receptor subfamily 0 group B member 1
go.drugbank.com/bio_entities/BE0000074TargetHumansNuclear receptor that lacks a DNA-binding domain and acts as a corepressor that inhibits the transcriptional activity of other nuclear receptors through heterodimeric interactions (PubMed:12482977, PubMed
Polypeptides: Nuclear receptor subfamily 0 group B member 1Synonyms: Nuclear receptor DAX-1Nuclear receptor subfamily 1 group D member 1
go.drugbank.com/bio_entities/BE0009347TargetHumansRepresses gene expression at a distance in macrophages by inhibiting the transcription of enhancer-derived RNAs (eRNAs). … Acts as a receptor for heme which stimulates its interaction with the NCOR1/HDAC3 corepressor complex, enhancing transcriptional repression.
Polypeptides: Nuclear receptor subfamily 1 group D member 1Leucine-rich repeat serine/threonine-protein kinase 2
go.drugbank.com/bio_entities/BE0009457TargetHumansTogether with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose-6-phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent
Polypeptides: Leucine-rich repeat serine/threonine-protein kinase 2Tyrosine-protein phosphatase non-receptor type substrate 1
go.drugbank.com/bio_entities/BE0010650TargetHumansReceptor for THBS1 (PubMed:24511121). Interaction with THBS1 stimulates phosphorylation of SIRPA (By similarity). … Involved in the negative regulation of receptor tyrosine kinase-coupled cellular responses induced by cell adhesion, growth factors or insulin.
Polypeptides: Tyrosine-protein phosphatase non-receptor type substrate 1Synonyms: Inhibitory receptor SHPS-1, Macrophage fusion receptorF-box-like/WD repeat-containing protein TBL1X
go.drugbank.com/bio_entities/BE0012106TargetHumansF-box-like protein involved in the recruitment of the ubiquitin/19S proteasome complex to nuclear receptor-regulated transcription units (PubMed:14980219).
Polypeptides: F-box-like/WD repeat-containing protein TBL1XPasireotide
go.drugbank.com/drugs/DB06663ApprovedInvestigationalPasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Categories: Somatostatin Receptor Agonists, Cytochrome P-450 CYP3A InhibitorsSynonyms: cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)Velaglucerase alfa
go.drugbank.com/drugs/DB06720ApprovedVelaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. … Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease.
Products: VPRIV ®, VPRIV 400 ÜNİTE İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 5 ADET